Infectious Complications Associated With the Use of Immune Checkpoint Inhibitors in Oncology: Reactivation of Tuberculosis After Anti PD-1 Treatment

Clinical Microbiology and Infection - United Kingdom
doi 10.1016/j.cmi.2017.12.003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Immune Checkpoint Inhibitors in the Treatment of Virus-Associated Cancers

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Review of Cancer Treatment With Immune Checkpoint Inhibitors

Wiener Klinische Wochenschrift
Medicine
2017English

Pd-1 Immune Checkpoint Blockade Improves Anti-Cd20 Based Immunotherapy in Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review

Cancers
Cancer ResearchOncology
2020English

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer
Oncology
2020English

Possible Abscopal Effect in Urothelial Carcinoma of the Upper Urinary Tract After Treatment With Immune Checkpoint Inhibitors

IJU Case Reports
2019English

Role of Immune Checkpoint Inhibitors in Gastrointestinal Cancer Treatment

Memo - Magazine of European Medical Oncology
OncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy